NCT03176238 - Study in Post-menopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer | Biotech Hunter

Enrollment

235

Participants

Timeline

Start Date

March 29, 2013

Primary Completion Date

January 29, 2019

Study Completion Date

January 29, 2019

Conditions

Post Menopausal Breast Cancer

Interventions

DRUG

everolimus

one 10 mg tablet or two 5 mg tablets of everolimus were administered orally once daily on a continuous dosing schedule starting on Day 1

DRUG

exemestane

25 mg tablet was administered orally once daily on a continuous dosing schedule starting on Day 1

Trial Locations (55)

2080

Novartis Investigative Site, Aryanah

2170

Novartis Investigative Site, Liverpool

2229

Novartis Investigative Site, Caringbah

2605

Novartis Investigative Site, Garran

3021

Novartis Investigative Site, St Albans

3084

Novartis Investigative Site, Heidelberg

3128

Novartis Investigative Site, Box Hill

3135

Novartis Investigative Site, Ringwood East

6527

Novartis Investigative Site, Rabat

6530

Novartis Investigative Site, George

7925

Novartis Investigative Site, Cape Town

Novartis Investigative Site, Western Cape

10048

Novartis Investigative Site, Taipei

10300

Novartis Investigative Site, Bangkok

10400

Novartis Investigative Site, Bangkok

10408

Novartis Investigative Site, Gyeonggi-do

10449

Novartis Investigative Site, Taipei

11420

Novartis Investigative Site, Jakarta

11941

Novartis Investigative Site, Amman

23561

Novartis Investigative Site, New Taipei City

27310

Novartis Investigative Site, Gaziantep

34890

Novartis Investigative Site, Kartal

34899

Novartis Investigative Site, Pendik / Istanbul

35040

Novartis Investigative Site, Izmir

40161

Novartis Investigative Site, Bandung

41944

Novartis Investigative Site, Taegu

50006

Novartis Investigative Site, Changhua

50200

Novartis Investigative Site, Chiang Mai

50212

Novartis Investigative Site, Semarang

50586

Novartis Investigative Site, Kuala Lumpur

55284

Novartis Investigative Site, Yogyakarta

56000

Novartis Investigative Site, Kuala Lumpur

80756

Novartis Investigative Site, Kaoshiung

83301

Novartis Investigative Site, Kaohsiung City

88586

Novartis Investigative Site, Kota Kinabalu

388325

Novartis Investigative Site, Karamsad

411013

Novartis Investigative Site, Pune

443380

Novartis Investigative Site, Suwon

519763

Novartis Investigative Site, Jeollanam-do

602739

Novartis Investigative Site, Busan

700000

Novartis Investigative Site, Ho Chi Minh City

422 004

Novartis Investigative Site, Nashik

753 007

Novartis Investigative Site, Cuttack